GlassScriptPhysician profile
Areej Mazhar
NPI 1235522426
$7,207.60
in general payments reported to CMS, 2019-2025
19 companies · $1,648 in 2025
The $1,648 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2020: $230 · 2021: $412 · 2022: $1,459 · 2023: $686 · 2024: $2,166 · 2025: $1,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,303 · Travel and Lodging: $2,128 · Education: $67.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,303.23 |
| Travel and Lodging | $2,128.18 |
| Education | $67.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,644.64 | 2024-2025 | Axios, Overstitch Endoscopic Suturing System, Exalt Model D |
| Janssen Biotech, INC. | $651.62 | 2020-2023 | Stelara |
| Janssen Scientific Affairs, LLC | $422.87 | 2021-2023 | Stelara |
| Abbvie INC. | $407.73 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $338.69 | 2019-2023 | Ocaliva |
| Ambu INC. | $260.48 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $237.09 | 2021-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.48 | 2022-2024 | Xifaxan |
| Cook Medical LLC | $151.46 | 2020-2023 | Fusion |
| Allergan, INC. | $147.27 | 2019 | |
| Mallinckrodt Hospital Products INC. | $147.11 | 2022 | |
| Shionogi INC | $125.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.56 | 2019 | |
| 3-D Matrix, INC. | $107.89 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $105.53 | 2023 | Dupixent |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $94.50 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.94 | 2021 | |
| Pfizer INC. | $20.28 | 2025 | |
| Novo Nordisk INC | $18.46 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Areej Mazhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.